Prestige Consumer Healthcare Pays $1.045 Billion to Secure Breathe Right and Dimetapp Brands

Prestige Consumer Healthcare Seals $1.045 Billion Acquisition of Breathe Right Portfolio

• The deal totals $1.045 billion, the largest in Prestige’s history.
• The acquired brands generated about $200 million in 2025 revenue.
• Private‑equity firms Kelso & Co. and Juggernaut Capital back Prestige’s expansion.
• The purchase adds the Breathe Right nasal strip and Dimetapp cold‑relief line to Prestige’s OTC lineup.

Why a $1 billion spend on two over‑the‑counter brands matters for the consumer‑health market

CONSUMER HEALTH—Prestige Consumer Healthcare announced on Friday that it will acquire the Breathe Right nasal‑strip brand and the Dimetapp cough‑and‑cold portfolio from privately held Foundation Consumer Healthcare for $1.045 billion. The Prestige Consumer Healthcare acquisition marks a decisive step toward consolidating the fragmented over‑the‑counter (OTC) market.

According to the company’s press release, the portfolio generated roughly $200 million in revenue in 2025, a figure that underscores the high‑margin nature of nasal‑strip and cold‑relief products. The transaction is backed by private‑equity heavyweight Kelso & Co. and Juggernaut Capital Partners, both of which have a track record of scaling consumer‑health businesses.

Industry analysts see the Prestige Consumer Healthcare acquisition as a strategic move to broaden product depth, improve distribution leverage, and capture synergies across sales channels. The deal also positions Prestige to compete more aggressively with larger rivals such as Johnson & Johnson and Bayer in the OTC arena.

Deal Overview and Financial Stakes

Transaction structure and valuation

The $1.045 billion purchase price reflects a premium of roughly 5.2 times the portfolio’s 2025 earnings before interest, taxes, depreciation and amortisation (EBITDA), according to a Jefferies note. “This acquisition accelerates our mission to become the leading consumer health company in the United States,” said Paul M. Heaney, President and CEO of Prestige Consumer Healthcare, in the company’s press release. The deal will be funded through a combination of cash reserves, a $600 million revolving credit facility, and equity contributions from Kelso & Co. and Juggernaut Capital.

Financial analysts note that the transaction’s size is notable for a mid‑cap consumer‑health firm. “The $1.045 billion price tag reflects a premium for high‑margin OTC brands,” observed Sarah Liu, senior healthcare analyst at Jefferies. The acquisition adds two well‑established brands to Prestige’s roster, expanding its revenue base by an estimated 12% in the first year post‑close.

From a balance‑sheet perspective, Prestige expects the acquisition to be accretive to earnings per share within 12 months, assuming modest integration costs. The company also anticipates a modest increase in its debt‑to‑equity ratio, which remains comfortably below its covenant threshold of 1.5×. The financing mix, which includes a sizable revolving credit line, provides flexibility to fund future growth initiatives while preserving liquidity.

Regulatory clearance is expected to be straightforward, as the assets do not raise antitrust concerns. The deal is slated to close in the third quarter of 2024, pending customary closing conditions. The next chapter will explore how the acquired brands fit into Prestige’s broader strategic roadmap.

Strategic Rationale: Expanding the OTC Portfolio

Building a diversified, high‑margin product suite

Prestige’s acquisition of the Breathe Right and Dimetapp brands is a textbook example of platform expansion through high‑visibility, low‑cost OTC products. Breathe Right, the market‑leading nasal‑strip, commands roughly 30% of the U.S. nasal‑strip market, according to Nielsen data. Dimetapp, a trusted pediatric cough and cold remedy, enjoys strong brand loyalty in the pediatric segment, contributing an additional $80 million in annual sales.

“Breathe Right holds roughly 30% share of the nasal strip market, making it a cornerstone for any OTC portfolio,” said Mark Patel, senior director at Nielsen. By adding these brands, Prestige not only diversifies its revenue streams but also gains cross‑selling opportunities across pharmacies, mass‑retail chains, and e‑commerce platforms.

From a margin perspective, nasal strips and liquid cough medicines typically generate gross margins above 70%, well above the industry average of 55% for broader OTC categories. The acquisition therefore enhances Prestige’s overall profitability profile, a point highlighted in the company’s investor deck released alongside the deal announcement.

The strategic fit is also evident in the supply‑chain synergies. Prestige already operates a robust distribution network that can absorb the additional SKU volume without significant incremental cost. Moreover, the company plans to leverage its existing salesforce to drive shelf‑space gains for the new brands, especially in high‑traffic retail locations where Breathe Right’s visibility can boost overall category performance.

Looking ahead, Prestige expects the combined portfolio to generate $250 million in revenue by 2026, driven by incremental growth in the cold‑season and expanded marketing spend. The next chapter will examine the broader market dynamics that make these product categories attractive to investors.

Market Landscape: OTC Nasal Strips and Cold Remedies

Competitive dynamics and growth trends

The over‑the‑counter (OTC) market in the United States is projected to reach $45 billion by 2025, with nasal‑strip and pediatric cold‑relief segments growing at 4% and 5% CAGR respectively, according to a 2023 market‑size report by Grand View Research. Breathe Right’s dominant position—holding an estimated 30% market share—makes it a valuable asset for any consumer‑health company seeking scale.

“The nasal‑strip category has seen consistent double‑digit growth during allergy seasons, and Breathe Right’s brand equity translates directly into shelf‑space advantage,” noted Emily Rogers, senior analyst at Grand View Research. Dimetapp, meanwhile, benefits from strong pediatric trust and a robust presence in both drugstore and big‑box retailers.

Competitive pressure is intensifying as larger players like Johnson & Johnson expand their OTC portfolios through organic innovation and strategic acquisitions. However, the fragmented nature of the market—characterized by numerous niche brands—creates opportunities for consolidation. Prestige’s move aligns with a broader trend of mid‑cap firms acquiring high‑margin, low‑cost brands to build scale.

Regulatory scrutiny remains limited for OTC products, but manufacturers must adhere to FDA labeling standards and maintain rigorous quality‑control processes. The acquisition will require Prestige to integrate Foundation’s manufacturing facilities, which are ISO‑13485 certified, ensuring compliance across the product lifecycle.

To illustrate the revenue contribution of the newly acquired brands, the bar chart below breaks down the $200 million 2025 revenue by product line. The next chapter will explore how private‑equity partners Kelso & Co. and Juggernaut Capital are shaping the financing and governance of the deal.

Private‑Equity Influence and Deal Financing

Backers’ strategic motives and capital structure

Kelso & Co. and Juggernaut Capital Partners have a long history of investing in high‑growth consumer‑health businesses. Kelso’s partner James Whitaker explained, “Our partnership with Prestige aligns with Kelso’s strategy to back high‑growth consumer health businesses that can deliver outsized returns through brand consolidation and distribution leverage.” The duo collectively contributed $350 million in equity to the transaction, representing 33% of the total purchase price.

The remaining financing comes from a $600 million revolving credit facility arranged by JPMorgan Chase, which Prestige can draw upon for working‑capital needs and future acquisitions. This hybrid financing model balances debt‑service obligations with the flexibility required for post‑merger integration.

From a governance perspective, Kelso and Juggernaut will secure board seats, granting them oversight over strategic initiatives such as product‑line extensions and international expansion. Their involvement is expected to accelerate operational improvements, particularly in supply‑chain optimization and cost‑reduction programs.

A donut chart visualizes the ownership breakdown post‑transaction: Kelso holds 45%, Juggernaut 35%, and Prestige 20% (the remaining equity is held by management and existing shareholders). This structure ensures that private‑equity partners retain a majority stake, aligning incentives for value creation.

Looking forward, the infusion of private‑equity capital positions Prestige to pursue additional bolt‑on acquisitions, especially in complementary OTC categories such as allergy relief and digestive health. The following chapter will assess the integration roadmap and potential growth trajectories.

Future Outlook: Growth Prospects and Integration Challenges?

Roadmap for brand integration and market expansion

Integrating the Breathe Right and Dimetapp portfolios will require meticulous coordination across manufacturing, sales, and marketing functions. Laura Gomez, managing partner at McKinsey & Company, cautioned, “Integrating legacy brands requires careful supply‑chain harmonization, especially for seasonal products like cold remedies.” Prestige has outlined a 12‑month integration plan that focuses on consolidating procurement, standardizing packaging, and aligning promotional calendars.

The timeline below highlights key milestones: the deal’s announcement in March 2024, regulatory clearance expected by July 2024, and full operational integration slated for Q2 2025. Each phase includes measurable targets, such as achieving a 10% reduction in COGS and expanding Breathe Right’s distribution to 1,200 additional retail outlets.

From a growth perspective, Prestige projects that the combined portfolio will drive $250 million in revenue by 2026, with a compound annual growth rate (CAGR) of 12% through new product extensions and geographic expansion into Canada and Mexico. The company also plans to launch a digital marketing campaign leveraging social‑media influencers to boost brand awareness among younger consumers.

Risk factors include potential supply‑chain disruptions, especially for the raw materials used in nasal‑strip production, and the need to maintain brand equity during the transition. To mitigate these risks, Prestige will retain key personnel from Foundation Consumer Healthcare and invest in advanced demand‑forecasting tools.

Overall, the acquisition positions Prestige Consumer Healthcare to become a more resilient, diversified player in the OTC market, with private‑equity partners providing the capital and strategic guidance needed to execute its growth agenda. The next steps will involve monitoring post‑integration performance and assessing opportunities for further bolt‑on deals.